|
|
Paul is co-head of the firm’s Securities and Public Companies practice. Paul represents public companies in business combinations and securities offerings, regularly advising clients on tender offers and other M&A engagements, on corporate governance matters, and on public and private sales of common stock, convertible notes, and debt instruments. He frequently handles transactions involving biotechnology, medical device, and pharmaceutical companies — including Covidien, Cubist, Ironwood, and Pfizer — and he has substantial experience representing entities organized in Massachusetts.
- Cubist Pharmaceuticals, a leading biopharmaceutical company, in a variety of corporate and securities matters, including its 2011 acquisition of Adolor Corporation for a combination of approximately $215 million in cash and contingent payment right and, in 2010, a $450 million convertible note offering.
- Pfizer, the world's largest research-based pharmaceutical company, in a variety of corporate and securities matters including its 2011 acquisition of Excaliard Pharmaceuticals, a biopharmaceutical company focused on the development of novel drugs for the treatment of skin scarring, and its its 2011 acquisition of Icagen, a biopharmaceutical company focused on small molecule drugs that modulate ion channel targets.
- Stryker, one of the world’s leading medical technology companies, in its acquisition of Concentric Medical, a medical device company focused on acute ischemic stroke intervention, for $135 million.
- inVentiv Health, a leading global provider of results-driven clinical, consulting and commercial services to the pharmaceutical and healthcare industries, in its 2011 acquisition of PharmaNet, a provider of global drug development services, on undisclosed financial terms, and in its related $390 million note offering
- Genzyme Corporation, one of the world’s leading biotechnology companies, in a variety of corporate matters, including, its 2011 sale to Sanofi for $20.1 billion in cash plus CVRs, and, in 2010, a proxy contest with entities affiliated with Carl Icahn, a cooperation agreement with Relational Investors, a $1 billion 144A debt offering, a $1 billion accelerated share repurchase, the $925 million sale of its Genetics business unit to Laboratory Corporation of America Holdings, and the $265 million sale of its Diagnostics business unit to Sekisui Chemicals Co.
- Underwriters, led by Citi, in the 2011 $54 million IPO of Tranzyme, a clinical-stage biopharmaceutical company.
- Covidien plc, a leading global provider of health care products, in several acquisitions, including, in 2010, its $2.7 billion acquisition of ev3, Inc., an endovascular device maker, and a related $1.5 billion debt offering.
- Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, in its 2010 $202 million IPO.
Honors & Awards
- Chambers USA: America's Leading Lawyers for Business (2011)
- The Best Lawyers in America (2006-2012)
©1996-2012 Ropes & Gray LLP. All rights reserved.
|
|
Education
-
JD, with distinction, Stanford Law School, 1993
-
BA, summa cum laude, Boston College, 1988
Bar Admissions
- Massachusetts, 1995
- California, 1993
|
|